Stanley Hirsch
Director/Board Member at Rimonyx Pharmaceuticals Ltd.
Active connections
Name | Gender | Age | Linked companies | Collaboration |
---|---|---|---|---|
Paul Gregor | M | - |
Rimonyx Pharmaceuticals Ltd.
Rimonyx Pharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology Rimonyx Pharmaceuticals Ltd. develops drugs targeted at glycosaminoglycan and protein interactions. It identified a series of novel anti-inflammatory compounds and has recently partnered its lead drug candidate, RX-111, for further preclinical and clinical development. It is focused on developing additional products for a variety of inflammatory and autoimmune indications. The company was founded in 2001 and is headquartered in Ness-Ziona, Israel | 23 years |
Regina Zhuk | M | - |
Rimonyx Pharmaceuticals Ltd.
Rimonyx Pharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology Rimonyx Pharmaceuticals Ltd. develops drugs targeted at glycosaminoglycan and protein interactions. It identified a series of novel anti-inflammatory compounds and has recently partnered its lead drug candidate, RX-111, for further preclinical and clinical development. It is focused on developing additional products for a variety of inflammatory and autoimmune indications. The company was founded in 2001 and is headquartered in Ness-Ziona, Israel | - |
Miki Ben-Dor | M | - |
Rimonyx Pharmaceuticals Ltd.
Rimonyx Pharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology Rimonyx Pharmaceuticals Ltd. develops drugs targeted at glycosaminoglycan and protein interactions. It identified a series of novel anti-inflammatory compounds and has recently partnered its lead drug candidate, RX-111, for further preclinical and clinical development. It is focused on developing additional products for a variety of inflammatory and autoimmune indications. The company was founded in 2001 and is headquartered in Ness-Ziona, Israel | - |
Orgad Laub | M | - |
Rimonyx Pharmaceuticals Ltd.
Rimonyx Pharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology Rimonyx Pharmaceuticals Ltd. develops drugs targeted at glycosaminoglycan and protein interactions. It identified a series of novel anti-inflammatory compounds and has recently partnered its lead drug candidate, RX-111, for further preclinical and clinical development. It is focused on developing additional products for a variety of inflammatory and autoimmune indications. The company was founded in 2001 and is headquartered in Ness-Ziona, Israel | - |
Alan Lewis | M | - |
Rimonyx Pharmaceuticals Ltd.
Rimonyx Pharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology Rimonyx Pharmaceuticals Ltd. develops drugs targeted at glycosaminoglycan and protein interactions. It identified a series of novel anti-inflammatory compounds and has recently partnered its lead drug candidate, RX-111, for further preclinical and clinical development. It is focused on developing additional products for a variety of inflammatory and autoimmune indications. The company was founded in 2001 and is headquartered in Ness-Ziona, Israel | - |
Connections Chart
Multi-company connection
Statistics
Country | Connections | % of total |
---|---|---|
Israel | 5 | 100.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Stanley Hirsch
- Personal Network